Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20…
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company…
Cash position bolstered through debt financing to support operations into the fourth quarter of 2023NEEDHAM, Mass., May 12, 2022 (GLOBE…
Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to…
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high…
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data…
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rdDose Level, Now Enrolling 4th…
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative…
--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and…
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of…